Zyrtec-D XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients with allergic rhinitis and nasal congestion increasingly report difficulty accessing Zyrtec-D XR (cetirizine HCl 5 mg / pseudoephedrine HCl 120 mg extended-release tablets) at their local pharmacies. While no official FDA shortage has been declared as of 2026, the unique regulatory environment surrounding pseudoephedrine-containing products creates recurrent availability challenges that clinicians should understand and proactively address with patients.

Current Availability Status (2026)

As of 2026, the FDA Drug Shortage Database does not list cetirizine/pseudoephedrine ER among current shortages. The drug has an established manufacturing base with multiple generic manufacturers producing cetirizine/pseudoephedrine ER 5mg/120mg tablets.

However, patients commonly experience localized stockouts driven by regulatory constraints rather than supply chain failures. This distinction is clinically important: the medication exists and is available — patients simply need guidance on accessing it effectively.

The Regulatory Landscape: Why Pseudoephedrine Products Are Difficult to Access

Zyrtec-D XR is subject to the Combat Methamphetamine Epidemic Act (CMEA) of 2005, which places strict requirements on all pseudoephedrine-containing products regardless of OTC status:

Must be stored behind the pharmacy counter; not accessible on open shelves

Purchaser must present government-issued photo ID and sign an electronic or paper log

Purchase limits: 3.6 g pseudoephedrine/day; 9 g pseudoephedrine/30 days per individual

Online direct-to-consumer sales are prohibited by federal law

These requirements reduce pharmacies' incentive to maintain large back-counter inventories, making seasonal demand surges more likely to cause stockouts. Patients may be frustrated that a product is simultaneously OTC and difficult to find — clinicians can help frame this correctly.

Clinical Pharmacology Review: Cetirizine/Pseudoephedrine ER

Cetirizine is a selective, peripherally acting histamine H1 receptor antagonist derived from hydroxyzine. Its low CNS penetration relative to first-generation antihistamines results in reduced sedation, though sedation remains possible. Pseudoephedrine is an oral sympathomimetic amine producing alpha-adrenergic-mediated vasoconstriction in nasal mucosa.

The extended-release bilayer formulation delivers cetirizine (Tmax ~2.2 hours) rapidly and pseudoephedrine (Tmax ~4.4 hours) over a sustained period, providing a 12-hour dosing window. Twice-daily dosing (every 12 hours, max 2 tablets/24 hours) is the standard regimen for adults and children 12 years and older.

Contraindications Prescribers Should Know

Absolute contraindications: Current or recent MAOI use (within 14 days), narrow-angle glaucoma, urinary retention, severe hypertension, severe coronary artery disease, hydroxyzine allergy

Use with caution: Hypertension (controlled), diabetes mellitus, ischemic heart disease, hyperthyroidism, renal impairment (consider dosage reduction), prostatic hypertrophy, elderly patients

Therapeutic Alternatives When Zyrtec-D XR Is Unavailable

When patients cannot access Zyrtec-D XR, the following clinical substitutions are appropriate:

Direct substitution (same drug class): Generic cetirizine/pseudoephedrine ER 5mg/120mg — bioequivalent; multiple generics available

Antihistamine/decongestant alternatives: Loratadine/pseudoephedrine (Claritin-D) — preferred for patients where sedation is a concern; Fexofenadine/pseudoephedrine (Allegra-D) — minimal sedation, ideal for working patients

Decongestant-free alternatives: Intranasal corticosteroids (fluticasone, mometasone, triamcinolone) — preferred first-line for chronic allergic rhinitis; montelukast — for patients with concomitant asthma; cetirizine alone for patients where decongestant is contraindicated

Prescribing a Prescription to Improve Access

Although Zyrtec-D XR is available OTC, prescribing it as a prescription drug can benefit patients in two ways: (1) it signals pharmacists to source the drug through their wholesaler if OTC stock is depleted, and (2) some insurance plans may cover it with a prescription, significantly reducing patient cost.

Resources for Patients

Encourage patients who are struggling to locate Zyrtec-D XR to use

medfinder for providers. medfinder is a paid service that calls pharmacies near the patient to check which ones have the medication in stock, then texts the patient the results — removing the burden of pharmacy-hunting from both the patient and the care team.